Project description
A novel analysis platform could find the silver bullet against an infection within hours
Bacteria are literally everywhere and the 'bad' ones are on the rise, developing resistance to antimicrobial drugs and flourishing in the face of years of pharmaceutical development aimed at protecting us. The types and doses of antibiotics have increased in response. Yet, prescribing the 'silver bullet' remains complicated by the lack of rapid diagnostic methods seeking to determine which antibiotic works best against the microbe that has caused the infection. Some of the most insidious infections result in an almost trial-and-error approach in which patients may have their treatments changed only when the chosen one is shown to be ineffective, sometimes after several days of therapy. The EU-funded Nanosynex project is bringing a same-day solution to market in the form of a table-top test platform with appropriate analysis software. Widespread use could enable personalised antibiotic therapy, an important weapon against growing antimicrobial resistance.
Objective
Antimicrobial Resistance (AMR), is the ability of microorganisms to resist to antibiotics treatment, contributes to 700,000 deaths a year (25,000 deaths in Europe). Besides, The financial implications of AMR proliferation are devastating for the global healthcare system. The current implementation of antimicrobial stewardship programs in hospitals has not been enough to mitigate the overuse and misuse of antibiotics. Current AST (Antimicrobial Susceptibility Testing) diagnostic methods are highly accurate but take too long (a few days) forcing doctors in many case to prescribe non-personalised treatments. The overuse and misuse of antibiotics, due to the lack of efficient solutions to detect bacterial resistance at an early stage, allows the emergence of “superbugs” and the spread of the resistant bacteria in the environment resulting in more infected patients and increasing the major global threat of Antimicrobial Resistance (AMR). Nanosynex product provides a revolutionary, low-cost, ultra-fast AST (Antimicrobial Susceptibility Testing) technology that delivers results in an average of only 4 hours in average, and as little as 2 hours for certain bacteria type. Nanosynex will allow physicians to get same-day AST results and to prescribe personalised and effective antibiotic treatment, with a unique test that will save at least one day of hospitalization per patient, as well as avoid pandemics outbreaks such as the current case of COVID-19. Consequently, Nanosynex will contribute to reduce the spread of resistant bacteria and significantly reduce the large economic burden associated with antimicrobial resistance. This EIC project aims the industrialization and scalability of Nanosynex benchtop and cards, performing the clinical trials to get the CE mark for its commercialisation across the EU. Nanosynex expects to reach a positive cash flow generation by the end of 2026 in the targeted scenario, with sales of +€27.5M.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
You need to log in or register to use this function
Keywords
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2Coordinator
5126112 Bnei Brak
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.